Aldevron News: gene therapy

Aldevron, Nature Technology Corporation team up to offer Nanoplasmids™ for gene therapy manufacturing

Aldevron has announced the immediate availability of NanoplasmidsTM and antibiotic-free RNA-OUT technology for use in gene therapy manufacturing. Through a license agreement with Nature Technology Corporation (NTC), Aldevron can now provide its clients the option of using NTC’s plasmid technology to provide a more efficient system for manufacturing viral vectors used in gene and cell therapy.

Read More

Aldevron announces ready-to-use helper plasmid for AAV manufacturing

New plasmid to reduce cost and timeline for gene therapy manufacturing

Aldevron, the world’s leading contract plasmid manufacturing organization, has announced the immediate availability of an off-the-shelf version of pXX6-80, a common adeno-associated virus (AAV) helper plasmid. The plasmid is designed to reduce the cost of AAV manufacturing and subsequent gene therapy applications, while helping Aldevron’s clients meet regulatory requirements.

Read More

Aldevron and the University of Minnesota collaborate in supporting Rare Disease Day

Aldevron is a sponsor for the Rare Disease Day program, "Gene Therapy for Rare Diseases: Promise and Challenges", presented by the University of Minnesota Center for Orphan Drug Research and Stem Cell Institute on February 23, 2018. Dr. Jakub Tolar, Dean, Medical School, University of Minnesota, will moderate the event, which will include presentations by University of Minnesota faculty and a representative from Abeona Therapeutics.

Read More